Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$146.01 USD

146.01
906,995

-0.83 (-0.57%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $143.59 -2.42 (-1.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Patterson (PDCO) Expands AI Solutions in Canada via Alliance

Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App

AMN Healthcare's (AMN) Manager Hub app, part of the ShiftWise Flex platform, revolutionizes workforce management for healthcare organizations with enhanced mobile capabilities and comprehensive insights.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services

Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?

Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.

Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health

Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.

Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis

Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.

Santanu Roy  headshot

Take the Zacks Approach to Beat the Markets: Snap, Naspers, e.l.f. Beauty in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Santanu Roy  headshot

Take the Zacks Approach to Beat the Markets: Robinhood Markets, Victory Capital, NVIDIA in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Santanu Roy  headshot

Take the Zacks Approach to Beat the Markets: Goldman Sachs, Rush Street Interactive, Atmus Filtration Technologies in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 9.68% and 3.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Quest Diagnostics (DGX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.